Remitting Neuropsychiatric Symptoms in COVID-19 Patients: Viral Cause or Drug Effect?

Numerous reports of neuropsychiatric symptoms highlighted the pathologic potential of SARS-CoV-2 and its relationship with the onset and/or exacerbation of mental illness. However, COVID-19 treatments, themselves, must be considered as potential catalysts for new onset neuropsychiatric symptoms in COVID-19 patients. To date immediate and long-term neuropsychiatric complications following SARS-CoV-2 infection are currently unknown. Here we report on five patients with SARS-CoV-2 infection with possible associated neuropsychiatric involvement, following them clinically until resolution of their symptoms. We will also discuss the contributory roles of chloroquine (CQ), and dexamethasone (DX) to these neuropsychiatric presentations. This article is protected by copyright. All rights reserved.